ClinicalTrials.gg
RecruitingNCT06678919Updated Apr 10, 2025

AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond

An observational study in Metastatic Colorectal Cancer (mCRC), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Recruiting at 7 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Colorectal Neoplasms with a site in Austria — 15 open to participants now, 20 under way, 7 of them phase 3. Colorectal Neoplasms · Austria.

Planned enrollment
11th of 25
500 · median 300
Started
2024
with 2 others
Observational
25 of 103
7 open now
Primary completion
2034-12
later than 19 of 19 live
Registered
95th of 103
by date
Lead sponsor
3 of 103
Arbeitsgemeinschaft medikamentoese Tumortherapie

Among the 103 studies in Colorectal Neoplasms with a site in Austria, this one is the 11th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2024, is one of 25 observational ones, reaches primary completion later than 19 of the 19 other live ones, and was the 95th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 103 studies in Colorectal Neoplasms with a site in Austria are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Colorectal Neoplasms with a site in Austria, or all of them as a file.
02

Study summary

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.

Read the detailed description

This registry aims at retrospectively and prospectively evaluating the treatment landscape and clinical outcome of mCRC ≥3L in a collective attempt by including multiple oncologic centers in Austria.

Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. Imaging studies ≥3L will be centrally collected in a virtual "imaging-bank" and tumor tissue samples of deceased patients will be stored in a central "bio-bank". Additionally, further biomaterial (e.g. ctDNA samples or DNA from DPYD genotyping) may be requested from the centres in case of specific research questions. The patient follow-up data will be obtained until patient death or loss to follow-up.

For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which have already been recorded in the patients' medical charts, is transferred to the electronic Case Report Forms. To maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patients' medical and other registry information throughout the lifetime of the registry.

A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients.

Data will be collected from all sites willing to participate.

03

Conditions studied

  • Metastatic Colorectal Cancer (mCRC)

Keywords

  • colorectal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Interested sites that treat patients in this indication will be invited to participate in this registry

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients ≥ 18 years with tissue-based diagnosis of mCRC
  • ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after .)

Exclusion criteria

Exclusion Criteria:

  • Due to the non-interventional design of this registry, there are no specific exclusion criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival with the respective treatment protocols ≥3L

    Time frame: 10 years

  2. Progression free survival

    Progression-free survival (PFS) with the respective treatments protocols ≥3L

    Time frame: 10 years

  3. Overall response rate (ORR)

    Overall response rate (ORR) with the respective ≥3L treatment protocols

    Time frame: 10 years

  4. Blinded Independent Central Review (BICR)

    Blinded Independent Central Review (BICR) based on the virtual imaging-bank

    Time frame: 10 years

  5. Identification of predictive biomarkers

    Identification of predictive biomarkers for mCRC patient sub-cohorts of interest based on the centrally-located bio-bank

    Time frame: 10 years

07

Study locations

7 of 7 sites recruiting
  • Ordensklinikum Linz, BHS - Interne I
    Linz, 4010, Austria
    Recruiting
    • Holger Rumpold, MD · Principal investigator
  • KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische Onkologie
    Linz, 4021, Austria
    Recruiting
    • Clemens Schmitt, MD · Principal investigator
  • LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)
    Rankweil, 6830, Austria
    Recruiting
    • Thomas Winder, MD · Principal investigator
  • Department of Internal Medicine III, Paracelsus Medical University Salzburg
    Salzburg, 5020, Austria
    Recruiting
    • Florian Huemer, Priv.Doz. Dr · Contactf.huemer@salk.at · +435725557082
    • Florian Huemer, Priv. Doz. Dr. · Principal investigator
    • Lukas Weiss, Priv. Doz. Dr. med. univ. · Sub investigator
    • Konstantin Schlick, Priv.-Doz. Dr. · Sub investigator
  • Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, Angiologie
    Steyr, 4400, Austria
    Recruiting
    • Georg Schreil, MD · Principal investigator
  • Klinikum Wels: Abteilung für Innere Medizin IV
    Wels, 4600, Austria
    Recruiting
    • Sonja Heibl, MD · Principal investigator
  • KH Zams: Innere Medizin Internistische Onkologie und Hämatologie
    Zams, 6511, Austria
    Recruiting
    • Ewald Wöll, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2034, 122 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 122 months is above that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 7, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Dec 2034
CompletionEst.
Dec 2034
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06678919
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Oct 31, 2024
Primary completion
Dec 2034 (estimated)
Completion
Dec 2034 (estimated)
Last update
Apr 10, 2025

Study contacts

Daniela Wolkersdorfer, Dr.
Contact
office@agmt.at
+436626404412

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion